• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

    5/5/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email

    The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner

    Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders

    CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhouse leaders in science, technology, medicine and capital markets who bring unparalleled expertise and decades of personal business success across biotechnology, neuroscience, venture capital, M&A, business and communications.

    The overarching mission of BioVie's Corporate Advisory Board is to support ongoing clinical development efforts, inform business strategy and enhance stakeholder engagement. Importantly, each advisor shares a deep-rooted personal connection to the neuroinflammatory conditions that the Company is hoping to address with its investigational drug candidate, bezisterim (NE3107). Their collective expertise will help the Company in a myriad of ways, including securing the capital needed for robust clinical development and educating key stakeholders about the critical roles that neuroinflammation and the associated insulin resistance play in the onset and progression of neuroinflammatory diseases, including Alzheimer's disease, Parkinson's disease and long COVID.

    "BioVie is built on deep scientific conviction – our board of directors, leadership and clinical teams joined from some of the world's most respected research institutions and pharmaceutical companies because they believe bezisterim has the potential to reshape how we treat Alzheimer's and Parkinson's," said Cuong Do, BioVie's President and CEO. "Now, we're expanding that foundation with leaders who have built category-defining companies across science, finance and technology. Their alignment with our mission affirms that BioVie is not only prepared to lead – but positioned to redefine what's possible in neurodegenerative care. BioVie is not standing still."

    "Despite decades of research, we still lack meaningful advancements in diseases like Alzheimer's and Parkinson's and a major shortcoming has been our historic underappreciation of neuroinflammation as not merely a byproduct, but a central force in neurodegeneration," said Zaldy Tan, MD, MPH, Director at Cedars-Sinai Memory & Aging Program and member of BioVie's Corporate Advisory Board. "My decision to join BioVie's Corporate Advisory Board is centered in the Company's focus on this underlying mechanism. As a clinician and researcher, I see the urgent need for new strategies that go beyond currently available treatments and aim to preserve cognition and function. BioVie's commitment to innovation in this space gives me hope for a future where we can improve both the quality and trajectory of life for millions of patients."

    Meet BioVie's Corporate Advisory Board:

    • Ugochi Owo (Chair) – Serial Entrepreneur & Operator: A strategic architect and serial entrepreneur, Ugochi Owo is widely known for her ability to build world-class teams and cultivate the kinds of relationships that move industries forward. As the founder of Flindel and a trusted operator across sectors, she brings sharp execution, deep network fluency and bold vision to BioVie's board at a pivotal moment of growth.



    • Zaldy Tan, MD, MPH – Director, Cedars-Sinai Memory & Aging Program: Director of the Cedars-Sinai Memory and Aging Program and a globally recognized leader in Alzheimer's research, Dr. Zaldy Tan brings decades of expertise in neurodegeneration, brain imaging and clinical trials. His insights into real-world patient outcomes and cognitive biomarkers will help shape BioVie's translational strategy and drive deeper engagement with the neurology community.



    • Kush Saxena – Global Fintech Veteran | Former CEO, GetNet, Former SVP MasterCard: Kush Saxena is a globally respected fintech executive with a track record of scaling financial infrastructure and leading complex, high-growth organizations. As former CEO of Santander's Getnet and EVP at Mastercard, he led major initiatives in digital commerce, data infrastructure and platform growth. Kush chairs and has co-founded Function Ventures, a leading fintech incubator and investor with a deep focus on value creation. Kush brings to BioVie a rare blend of financial precision, platform thinking, and operational scale – positioning him as a strategic force in guiding capital markets readiness, partnership structuring and enterprise growth.



    • Tim Gardner, PhD – Associate Professor of Neuroengineering, University of Oregon | Co-Founder, Neuralink: Dr. Tim Gardner is a pioneer in brain–machine interface innovation. As a co-founder of Neuralink, he helped shape the current vision for brain–machine interfaces. Now at the University of Oregon's Knight Campus, his research focuses on neural circuit function and technology that interfaces directly with the brain. Dr. Gardner brings to BioVie deep expertise in neurological systems, data-driven modeling and innovation at the frontier of brain health – supporting the Company's push to redefine how neurodegenerative diseases are understood and treated.



    • Justina Omokhua – Senior Vice President, Parkwood Entertainment | Former Global Head of Content Strategy, Apple: Justina Omokhua is a seasoned marketing executive with a track record of leading brand strategies at major companies, including Apple, Endeavor and Nokia. Currently serving as Senior Vice President at Parkwood Entertainment, she oversees day-to-day operations and brings a global perspective to brand building. Her expertise in crafting compelling narratives and engaging diverse audiences is vital for BioVie's mission to raise awareness and connect with stakeholders.



    • Gregory Nguyen – Technologist | Private Markets Strategist: Gregory Nguyen is a technologist and private investor with a background in defense systems, semiconductors and digital assets. An early investor in Marvell, Broadcom, MicroStrategy and Bitcoin, he brings strategic insight across emerging tech, biopharma and capital markets. At BioVie, he provides strategic insight at the intersection of innovation, capital and long-view investing to help position the Company for durable value creation in a rapidly evolving healthcare landscape.



    • Casey Woo – CEO, Operators Guild | Seven-Time High-Growth CFO/COO: Casey Woo is a proven operator and investor with two decades of experience scaling high-growth startups across industries and stages. As CEO and founder of Operators Guild (a global community of over 1,000 top-tier operators) and General Partner at FOG Ventures, Woo sits at the nexus of executional excellence and next-generation venture leadership. At BioVie, he brings financial rigor, operational discipline, and access to one of the strongest execution networks in tech to ensure the Company is poised to scale with precision.

    About Bezisterim        

    Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID.

    BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease.

    In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) has been completed, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events.

    In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe recently began enrollment in the Phase 2 ADDRESS-LC study, a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ("brain fog") and fatigue.

    About BioVie Inc.        

    BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

    Forward-Looking Statements 

    This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

    References        

    1 Cleveland Clinic. Parkinson's Disease. Last reviewed: 2022 Apr 15.

    2 Jurcau A, Andronie-Cioara FL, Nistor-Cseppento DC, et al. Int J Mol Sci. 2023;24:14582.

    3 Pajares M, Rojo AI, Manda G, et al. Cells. 2020;9:1687.

    4 Isik S, Kiyak BY, Akbayir R, et al. Cells. 2023;12:1012.

    5 Zagare A, Hemedan A, Almeida C, et al. Mov Disord. 2025;40(1):67-76.

    6 Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. Nutrients. 2023;15(16):3585.

    7 Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.

    8 Postuma RB, Berg D, Stern M, et al. Mov Disord. 2015;30(12):1591-1601.

    9 Kalia LV and Lang AE. Lancet. 2015;386(9996):896-912.

    For Investor Relations Inquiries: 

    Contact: 

    Bruce Mackle 

    Managing Director 

    LifeSci Advisors, LLC 

    [email protected]

    For Media Inquires

    Melyssa Weible

    Managing Partner, Elixir Health Public Relations 

    Ph: +1 201-723-5705

    [email protected]



    Primary Logo

    Get the next $BIVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    SEC Filings

    See more
    • SEC Form PRE 14A filed by BioVie Inc.

      PRE 14A - BIOVIE INC. (0001580149) (Filer)

      5/8/25 5:20:30 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14C filed by BioVie Inc.

      PRE 14C - BIOVIE INC. (0001580149) (Filer)

      5/7/25 5:20:08 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIOVIE INC. (0001580149) (Filer)

      3/28/25 5:00:27 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Do Cuong V bought 10,000 shares (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      3/6/24 5:12:41 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      12/1/23 6:26:32 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Leadership Updates

    Live Leadership Updates

    See more

    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

      CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

      6/4/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces the Appointment of a New Chief Medical Officer

      RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

      11/1/21 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioVie Inc.

      SC 13G - BIOVIE INC. (0001580149) (Subject)

      10/25/24 4:01:25 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioVie Inc.

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      6/25/24 7:47:33 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      3/10/23 5:15:43 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:26:37 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:24:53 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:21:05 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

      Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

      7/22/22 7:51:28 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on BioVie with a new price target

      B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

      11/30/21 8:23:48 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Financials

    Live finance-specific insights

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

      CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t

      11/20/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care